Vertex Re-rating Ahead? Why Povetacicept Could Be the Growth Catalyst Investors Have Been Waiting For
Vertex looks expensive on headline multiples but the arrival of povetacicept as a potential follow-on growth driver - combined with recent positive rare-disease data and a strong cash/FCF profile - justifies an upgrade. This trade idea lays out an entry at $472.00, a stop at $445.00 and a target of $520.00 over a 180 trading-day horizon.